

Original Article

Design, Development and Immunogenic Evaluation of a Novel LipI32 Recombinant Protein of Local Pathogenic *Leptospira* Serovars

Bakhshandeh, N¹, Tebianian, M^{2*}, Khaki, P³, Esmaelizad, M⁴, Saadatmand, S¹

1. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.

2. Department of Immunology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.

3. Department of Microbiology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.

4. Department of Biotechnology, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran.

How to cite this article: Bakhshandeh N, Tebianian M, Khaki P, Esmaelizad M, Saadatmand S. Design, Development and Immunogenic Evaluation of a Novel LipI32 Recombinant Protein of Local Pathogenic *Leptospira* Serovars. *Archives of Razi Institute*. 2025;80(1):103-115. DOI: 10.32592/ARI.2025.80.1.103



Copyright © 2023 by



Razi Vaccine & Serum Research Institute

ABSTRACT

Leptospirosis, a significant yet often overlooked zoonotic disease, is distributed worldwide, particularly in tropical and subtropical regions. The manifestation of its symptoms can be deceptive, often leading to misdiagnosis due to its resemblance to other infectious diseases. The development of rapid diagnostic tests and the identification of potential vaccine candidates for leptospirosis pose significant challenges. Surface-exposed antigens, found on the outer layer of *Leptospira*, likely contribute to the initial interactions between the host and the pathogen. LipI32 is highly conserved and exclusively produced by pathogenic *Leptospira*, and it plays a significant role in a prominent immunogen in leptospirosis. The objective of this study is to establish the optimal conditions for the expression and purification of the rLipI32 protein of Iranian pathogenic *Leptospira* and to assess its ability to stimulate cellular and humoral immune responses. A comprehensive analysis of all LipI32 protein sequences was conducted using the NCBI database. The codon sequences of serovars were designed and synthesized, and one local dominant LipI32 pattern was selected after optimization. The construct was sub-cloned into a pET32a+ vector with His-tag and Trx, then transformed into *E. coli* (BL21) for expression using IPTG. Subsequent purification and confirmation by immune blotting were then performed. BALB/c mice (4-6 weeks old) were vaccinated with three doses containing 50 mg of rLipI32, with a 14-day interval, and compared with controls. The humoral immune response and the cytokine profile were evaluated using an indirect sandwich ELISA test. The results demonstrated that the rLipI32 protein exhibited elevated levels of expression in the presence of 0.5 mM IPTG following a 16-hour incubation period at 22°C. The optimal conditions for the Ni-NTA pull-down process entailed a one-hour binding period at 37°C, followed by five washing steps and the use of an elution buffer with a pH of 7.4 and a 0.3 mM concentration of imidazole. This process successfully purified the rLipI32 protein in soluble form. The administration of rLipI32 resulted in elevated total antibody titers ($p < 0.05$) and a significant increase in cytokine levels ($p < 0.05$). Consequently, rLipI32 was found to potentially stimulate specific humoral and cellular immune responses. It has been proposed that this agent could be further utilized for immune dominant LipI32-based diagnosis and has potential as a subunit vaccine.

Article Info:

Received: 15 October 2024

Accepted: 19 November 2024

Published: 28 February 2025

Corresponding Author's E-Mail:
mtebianian@rvsri.ac.ir

Keywords: *Leptospira*, Recombinant protein LipI32, Gene Expression, Purification, Immune Response.

1. Introduction

Leptospirosis is a disease caused by pathogenic *Leptospira* bacteria and is deemed to be the most common re-emerging zoonosis worldwide, resulting in high mortality and morbidity (1,2). From a financial perspective, it is considered to be a huge burden for health systems and farming sectors (3,4). A global study on this disease showed that almost 100,000 severe cases are reported annually (5). This disease is transmitted via occupational exposure or travel, by direct or indirect contact with contaminated water, soil or the urine of animals (1,5,6). Although various organs can be affected, the lungs and kidneys have often been identified as the main targets for invasion (7,8). The diagnosis remains challenging, since this illness is frequently misdiagnosed with other febrile diseases possessing similar symptoms (8,9). Therefore, vaccination is considered to be a practical alternative for its management. Leptospirosis, an illness caused by pathogenic *Leptospira* bacteria, is regarded as the most prevalent emerging zoonosis on a global scale. It is associated with a high mortality and morbidity rate (1, 2). From a financial perspective, it is considered to be a significant financial burden for health systems and agricultural sectors (3,4). A global study on the disease revealed that nearly 100,000 severe cases are reported annually (5). The disease is transmitted through occupational exposure or travel, by direct or indirect contact with contaminated water, soil, or the urine of infected animals (1, 5, 6). While the disease has the potential to affect various organs, it predominantly targets the lungs and kidneys (7,8). The diagnosis of the disease is challenging because it is frequently misdiagnosed with other febrile diseases that present with similar symptoms (8, 9). Therefore, vaccination is considered a practical alternative for its management. In certain countries, whole-cell or inactivated vaccines have been authorized for utilization in animals with the objective of preventing various types of *Leptospira* infections and safeguarding humans by mitigating the transmission of disease (10,11). However, these vaccines have limitations, including a lack of cross-protection against heterologous serovars and the inability to provide long-term protection. Furthermore, these vaccines have been associated with the occurrence of adverse effects (12,13,14). Outer membrane proteins (OMPS), which are expressed on the surface of pathogenic strains, are also of interest in this regard (15,16). A significant body of research has identified numerous OMPs and demonstrated their ability to bind to the extracellular matrix of host cells. The interaction of these proteins with host factors, coupled with the growing understanding of OMPs, has prompted some researchers to explore their potential as vaccine candidates and diagnostic tools (17, 18). The diagnosis based on recombinant proteins offers certain advantages and can circumvent the issues associated with culture-based techniques (19, 20). The largest category comprises lipoprotein OMPS, which are designated based on their molecular weights and constitute a substantial proportion of

the outer membrane in comparison to other proteins. This group encompasses Lip121, Lip132, Lip136, Lip141, Loa22, and others (15, 21, 47). Of particular interest is Lip132 (also known as Hap1), a 32-kDa lipoprotein exclusively present in the outer membrane of pathogenic bacteria (22, 23). This protein has been identified in patients' sera and has been expressed both in vitro and in vivo in the early phase of infection (24). Lip132, a protein that exhibits significant conservation among pathogenic *Leptospira* species, serves as a reliable target for diagnostic testing and research on leptospirosis. It is anchored to the outer membrane through a cysteine-bound fatty acid at the N-terminal and interacts with zymogen plasminogen, which generates plasmin (25, 26). Additionally, Lip132 has been observed to bind to the proteoglycan receptors present on the cell surface. This protein is regarded as being highly immunogenic and has been the subject of extensive investigation as a potential diagnostic candidate for leptospirosis and the development of a subunit vaccine (27-29). Humoral responses were previously considered adequate for immunity against the disease; however, recent studies have highlighted the critical role of cell-mediated responses, specifically Th1 lymphocytes, in combating infections. These responses involve the activation of macrophages, leading to the production of gamma interferon (IFN- γ), which in turn facilitates the destruction of bacteria (30). The Th2-mediated immune response is commonly linked to interleukin-4 (IL-4) secretion, and it has been stated that the induction of IL-4 could play a significant part in augmenting antibody production (31, 32). Given the paucity of reports on the production and immunological assay of Lip132 in Iranian local isolates, the present study focused on the expression, purification, and assessment of immune responses to rLip132 from pathogenic *Leptospira* among Iranian serovars.

2. Materials and Methods

2.1. Bioinformatics Studies and Construction of the pET32-Lip132 plasmid Synthesis of Codon-Optimised Lip132 Gene

In this study, all local prevalent pathogenic *Leptospira* serovars were investigated, including the six standard serovars: Canicola, Autumnalis, Hardjo, Icterohaemorrhagiae, Pomona, and Grippityphosa were obtained from the reference laboratory of *Leptospira* at Razi Vaccine and Serum Research Institute in Iran. A total of 24 complete coding sequences of Lip132 protein deposited in GenBank until August 2017 in the NCBI database were collected using the BLAST online software (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) (Table 1). A comparative analysis of the protein sequences was conducted using the Meg Align software. The local Lip132 protein pattern was then employed as the foundation for the construct design, taking into account the observed polymorphisms. The initial 20 amino acids in the signal peptide of Lip132 were excised, and 756 coding nucleotide sequences were optimized by the Codon Optimization tool

Table 1. BLAST search results of lipL32 genes of *Leptospira* used for phylogenetic analysis.

No.	Accession No	Serovar	No.	Accession No	Serovar	No.	Accession No	Serovar
1	AY609325	<i>Australis</i>	17	JN831363	<i>Canicola</i>	33	KC800987	<i>Pomona</i>
2	AB094437	<i>Australis</i>	18	AY763509	<i>Canicola</i>	34	AY609323	<i>Pyrogenes</i>
3	AB094435	<i>Autumnalis</i>	19	JN886739	<i>Sejroe Hardjo</i>	35	HM449749	<i>Pyrogenes</i>
4	AY609324	<i>Autumnalis</i>	20	AY461905	<i>Sejroe Hardjo</i>	36	JN886738	<i>Grippotyphosa</i>
5	JN210551	<i>Autumnalis</i>	21	AY442332	<i>Sejroe Hardjo</i>	37	AY609327	<i>Grippotyphosa</i>
6	KC800989	<i>Autumnalis</i>	22	KC800991	<i>Sejroe Hardjo</i>	38	EU871723	<i>Grippotyphosa</i>
7	EU526391	<i>Autumnalis</i>	23	GU592525	<i>Sejroe Hardjo</i>	39	GU592524	<i>Grippotyphosa</i>
8	AF366366	<i>Autumnalis</i>	24	AB094433	<i>Icterohaemorrhagiae</i>	40	AY776292	<i>Javanika</i>
9	GU592526	<i>Autumnalis</i>	25	AY423075	<i>Icterohaemorrhagiae</i>	41	AY609332	<i>Wolffi</i>
10	AY461902	<i>Autumnalis</i>	26	KC800993	<i>Icterohaemorrhagiae</i>	42	AY568679	<i>Lai</i>
11	DQ092412	<i>Canicola</i>	27	KC800992	<i>Icterohaemorrhagiae</i>	43	AY609322	<i>Borgpeterseni Ballum</i>
12	AB094434	<i>Canicola</i>	28	GU183106	<i>Icterohaemorrhagiae</i>	44	AY461900	<i>Borgpeterseni Javanika</i>
13	HM026175	<i>Canicola</i>	29	AY461910	<i>Pomona</i>	45	EU526390	<i>Borgpeterseni Javanika</i>
14	AY609321	<i>Canicola</i>	30	AF181553	<i>Pomona</i>	46	EU526389	<i>Borgpeterseni Javanika</i>
15	AJ580493	<i>Canicola</i>	31	EU871716	<i>Pomona</i>	47	AY609330	<i>Borgpeterseni Tarassovi</i>
16	KC800990	<i>Canicola</i>	32	KC800988	<i>Pomona</i>	48	AF245281	<i>Borgpeterseni Copenhageni</i>

(Figure 1). Two recognition sites, EcoRI and XhoI, were strategically incorporated into the flanks of the LipL32 nucleotide sequence. Subsequently, the three-dimensional structure of the selected sequence was thoroughly analyzed using ExPASy software. The DNA sequence was synthesized by General Bio Systems, Inc., USA. The synthetic DNA was subsequently cloned into the pET32a+ expression plasmid, resulting in the creation of the pET32a+LipL32 recombinant vector. The N-terminal TRX tag sequence was selected to enhance the solubility of the recombinant LipL32 protein. The c-terminal of LipL32 was modified with six histidine residues to facilitate affinity purification by nickel resin.

2.2. Transformation, Expression and Purification of recombinant LipL32 protein

The recombinant plasmid of pET32a-LipL32 was transformed into *E. coli* BL21 (DE3) through a cold CaCl₂ treatment followed by a heat shock procedure and cultured in LB medium supplemented with 50 µg/mL of ampicillin. To confirm the positive recombinant clones selected on ampicillin plates, the related plasmids were extracted from bacterial cells using the Plasmid Mini extraction kit (Roche, Germany), following the manufacturer's protocol. One milliliter of an overnight culture of bacteria containing the recombinant plasmid was transferred to 50 milliliters of liquid 2YT medium containing 50 µg/mL of ampicillin. The mixture was then incubated overnight at 37°C with continuous shaking at 150 rpm. The bacterial growth was then monitored until it reached the mid-log phase (OD₆₀₀ nm) at an optical density of approximately 0.8 at 600 nm. To induce expression, various amounts (0.1 to 0.5 mM) of isopropyl β-D-thiogalactopyranoside (IPTG, Sigma-Aldrich, Korea) were added to the suspension. Samples of 1 ml were drawn at hourly intervals (0, 4, 8, and 16 h) and at different temperatures (22°C, 30°C, and 37°C) after induction. The samples were then subjected to

centrifugation at 5000 rpm for 5 min to obtain the pellet. The bacterial pellets were stored at -20°C for subsequent processing. The total proteins were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with unstained protein markers (Thermo Scientific, Lithuania). Induced cells were lysed in phosphate buffered saline (PBS) containing 10 mM imidazole and sonicated (5 cycles, 1 minute each, with 1 minute of intervals) on ice. Protease inhibitor, Phenyl Methyl Sulfonyl Fluoride (PMSF) (Sigma-Aldrich, United States), was added to inhibit probable protease activity. Subsequently, the lysate was subjected to a centrifugation process at 15,000 rpm at a temperature of 4°C for a duration of 15 minutes. Thereafter, the resulting soluble and insoluble fractions of the recombinant protein were subjected to an analysis through the utilization of a 10% SDS-PAGE method. SDS-PAGE analysis was conducted after cell disruption using ultrasound. This analysis revealed that the protein content in the soluble fraction was considerably higher than in the pellets. Following sonication, the contents were subjected to a centrifugation process at 15,000 rpm for a duration of 10 minutes. Subsequently, the purification of the recombinant protein was undertaken through the implementation of a Ni-NTA chromatography procedure, facilitated by a native buffer system in accordance with the protocol stipulated by Thermo Scientific (48). Initially, 100 µL of nickel resin containing ethanol were subjected to centrifugation at 3000 rpm at 4°C for 2 minutes, with the objective of removing the ethanol. Subsequently, the resin was equilibrated with a volume of buffer equal to twice the initial volume, which was composed of Phosphate Buffered Saline (PBS) with a pH of 7.4. This step ensured complete dissolution of the protein. The resin was then subjected to centrifugation under the same conditions as previously described. To ensure effective separation, the recombinant protein present in the upper layer of the solution was




Figure 1. Final map sequence generated from bioinformatics analysis of the target DNA.

subjected to centrifugation at 3000 rpm, 4°C, and 5 minutes. Following this, 10 ml of the protein-containing solution was added to the nickel resin, which was then incubated at 37°C in a shaker incubator for one hour. Subsequently, the resin was washed five times for 20 minutes on the protein-binding resin. Subsequent to the completion of each step, a process of centrifugation was executed under the previously established conditions. The resultant upper layer, or "supernatant," was then discarded. Subsequently, 100 µL of Elution Buffer (PBS-Imidazole) was added to the protein sample and shaken for 15 minutes at room temperature. It is noteworthy that, in each step, centrifugation was performed under the same conditions as before, with the difference that this time the preceding step's residual material was retained as the protein-containing solution. This step was repeated three times. Elutions 1 to 3 were separated for confirmation and observation of protein bands using SDS-PAGE. It is noteworthy that all purification buffers are composed of PBS and imidazole. The utilization of imidazole in this process is crucial for the elimination of non-specific proteins, thereby ensuring the purity and specificity of the target protein. In the washing buffer and equilibration buffer, the concentration of imidazole (25 mM) is kept low to prevent non-specific binding to the HIS tag, thereby allowing only the target proteins to bind to nickel. This strategy ensures that non-specific proteins are effectively washed away from the column, thereby enhancing the purity of the eluted protein. In the Elution buffer, the concentration of imidazole (250 mM) is higher, which consequently increases the likelihood of His-protein binding to nickel (33).

2.3. Measurement of Purified Recombinant Protein and Western Blotting Analysis

The quantification of the recombinant protein was carried out using the Bradford protein assay. To establish a standard curve, different concentrations of 0.25 mg/mL BSA (Bovine Serum Albumin) were utilized. Ten dilutions of BSA were prepared within a range of 0 to 10 µg/µL protein as a standard reference in deionized water. Subsequently, 200 µL of Bradford reagent was added to each dilution, resulting in a total volume of 1 mL. The purified recombinant protein was then subjected to Western blot analysis. The protein was transferred to a nitrocellulose membrane and probed with a HRP-conjugated anti-6x His-Tag antibody (diluted 1:5000) (Abcam, USA). The blocking step was performed by 1% BSA in PBS containing 0.1% Tween 20 (T-PBS), and 4-choloro-1-naphthol was used to visualize protein bands.

2.4. Immunization

Female inbred BALB/c mice, aged 6 to 8 weeks, with a body weight range of 20 to 25 grams, were obtained from the Razi Vaccine and Serum Research Institute in Karaj, Iran. These mice were randomly assigned to four groups of ten mice each and were permitted a week to acclimate to their new housing conditions. To assess the immunogenicity of rLip132, the mice were immunized three times by subcutaneous injection with 20 µg of rLip132 protein formulated with and without Freund's incomplete adjuvant on days 1, 14, and 28. The negative control group was inoculated with and sterile PBS, and as a positive control (Adj group), an equal amount of the adjuvant was received. Blood samples were obtained from the retro-orbital venous sinus on day 0 (before immunization) until

the 60th day with 10-day intervals (Table 2). The serum samples were separated by centrifugation (5000 rpm, 4°C, 5 minutes) and stored in -20°C to measure the antibody response. Spleens were isolated for the detection of cytokines.

2.5. Total IgG-ELISA for Anti R-LipI32

Blood was collected using the retro-orbital bleeding method, and the levels of specific IgG against r-LipI32 were measured using indirect ELISA. The optimal dilution for the antisera and antigen coating were determined using a checkerboard titration method. In summary, 96-well immunoplates (Jet Biofil, Guangzhou, China) were coated with 100 μ L (5 μ g/mL) of purified rLipI32 diluted in coating buffer (0.1 M Na₂CO₃, 0.1 M NaHCO₃, pH 9.5) (Merck, Germany) and incubated overnight at 4°C. Following three washes with 1.00x PBS containing 0.05% Tween 20 (PBST), non-specific binding sites were blocked using 3% BSA at 37°C for one hour. 100 μ L of diluted mouse sera (1/100) was added to each well and the plates were incubated at 37°C for 1 h. After washing the wells (three times with PBST), the rabbit anti-mouse HRP-conjugated IgG antibody (Sigma Aldrich, Germany) (1:15,000) was added and incubated at 37°C for 1 h. Following a third series of washes with PBST, 50 μ L of 3,3',5,5'-tetramethylbenzidine (TMB) (Sigma-Aldrich) was added to each well and incubated in the dark at room temperature for 20 minutes. The reaction was then halted with 100 μ L of 1M H₂SO₄. The optical density was subsequently measured using an ELISA plate reader (Bio Tek, Elx 800) at a wavelength of 450 nm.

2.6. Cytokine Expression Assay

Spleens from immunized mice were isolated 14 days after the last immunization, and splenocytes were collected after red blood cell lysis under aseptic conditions. A single-cell suspension of splenocytes was created by pressing homogenized spleens through a fine nylon mesh. The cells (3 \times 10⁶ cells/ml) were then added in complete RPMI 1640 (Sigma, USA) containing 10% fetal calf serum and were stimulated with 5 μ g/ml rLipI32 at 37°C in a 5% CO₂ incubator. Following a 60-hour stimulation period, the culture supernatants were harvested, and the levels of IFN- γ and IL-4 were measured using a commercial ELISA kit (Karmania Pars Gene, Iran) according to the manufacturer's protocol.

2.7. Statistical Analysis

All statistical analyses were performed using GraphPad Prism software (version 6; GraphPad Software Inc., San Diego, USA). One-way analysis of variance (ANOVA) was employed to assess the differences in antibody titers among the various groups. This statistical approach enables the comparison of means across multiple groups, thereby facilitating the identification of any significant variations in the antibody responses. Subsequently, analysis of variance and Tukey's test were employed to compare levels of cytokine production. This statistical approach enables the assessment of significant differences among multiple

groups, thereby providing insights into the effects of various treatments or conditions on cytokine levels. The results obtained were expressed as the mean and standard deviation (SD). Statistical significance was determined by setting a p-value threshold of 0.05. It is imperative to note that all experiments were meticulously executed in duplicate, with three biological samples per group, to ensure the robustness of the findings and the reliability of the results.

3. Results

3.1. Sequence Analysis and Construction of Expression Vectors

The LipI32 protein sequence contains 272 amino acids and has a molecular weight of 29.9 kilodaltons (kDa), as determined using the ExPasy-translate online tool and Editseq software. Bioinformatics analysis suggests that LipI32 encodes a membrane protein. The analysis of the LipI32 protein sequences revealed a dominant pattern with extensive coverage of high prevalence pathogenic serovars in Iran, which was selected as the primary sequence. The reference sequence was optimized for preferred codon usage in *E. coli*, and the signal peptide was removed. The redesigned sequence consists of 771 bp. The designed sequence was then employed to create an expression vector, designated as LipI32-pET32a(+), by inserting it into the EcoRI and XhoI restriction sites. This vector was engineered to align with Trx and six-His tags at the N-terminal end. This resulted in a protein with an expected molecular weight of approximately 38kDa. Figure 2 compares the two structures, which show 100% similarity in the lipI32 region. This indicates that the *trx* and *lipI32* segments have folded separately and that the structure of *lipI32* remains unchanged. Consequently, it is anticipated that the structural epitopes will also remain unaltered. The gene construct was synthesized by the General Biosystems Company (Durham, USA). A comparative analysis was conducted between the 24 complete LipI32 full-length genome sequences (272aa) of the *Leptospira* serovars described in Table 1 and the phylogenetic tree. According to the results presented in Figure 3(A), all serovars have been classified into two primary clusters based on the LipI32 protein. The first cluster comprises two serovars: *johnsonii* (protein number WP-108927686.1) from Australia and *hartskeerlii* (protein number WP-100707095.1) from Brazil. Conversely, 17 other serovars were classified into a second cluster, which itself consisted of several subclusters. The results demonstrated 0.03% divergence among the serovars utilized in this study (Figure 3A). The phylogenetic tree in Figure 3(B) revealed a divergence of 0.0020% among local serovars, as determined by protein sequence analysis of the LipI32. The percentage of similarity and divergence among registered Iranian serovars in the gene bank was analyzed based on protein LipI32 sequence using MegAlign software. The highest level of similarity reported was 100%, while the lowest level of dissimilarity was 98.7%. *Automanalis* (AGO95575.1)

Table 2. Groups of mice and injection preparations used in this experiment.

Group	Dose	Prime (1 Day)	Boost 1 (14 Day)	Boost 2 (28 Day)
Target+Adj.	20 μ g	rLipL32+ CFA (50:50)	rLipL32+ IFA (50:50)	rLipL32+ IFA (50:50)
Target	20 μ g	rLipL32	rLipL32	rLipL32
Vaccine	50 μ l	<i>Leptospira</i> vaccine	<i>Leptospira</i> vaccine	-----
Neg. control	100 μ l	PBS	PBS	PBS
Adj. control	100 μ l	CFA	CFA	CFA

Note: *CFA: Complete Freund's adjuvant * IFA: Incomplete Freund's adjuvant




Figure 2. A. The tertiary structure of the lip32 protein. B. The tertiary structure of the expressed fusion protein with trx.




Figure 3. A phylogenetic tree was constructed using the protein sequences of aligned LipL32, employing the neighbor joining method using MEGA11 software. A. The phylogenetic tree analyzed the sequence of the lipL32 protein in both native and non-native serovars in Iran were submitted to GenBank used in this research. B. The phylogenetic tree analyzed the sequence of the lip32 protein in pathogenic serovars native to Iran used in this study, consisting of eleven leptospira serovars.

demonstrated 100% similarity with *Canicola* (AGO95576.1) and also with serovars *Serio hardjo* (AFC76104.1), *Icterohaemorrhagiae* (AGO95578.1) (AGO95579.1), and *Grippotyphosa* (AFC76103.1). *Grippotyphosa* exhibited 100% similarity with *Canicola* (AGO95576.1), *Serio hardjo* (AGO95577.1), and (AFC76104.1), as well as *Icterohaemorrhagiae* (AGO95578.1) (AGO95579.1). The two serovars of *Icterohaemorrhagiae*, namely (AGO95578.1) and (AGO95579.1), exhibited 100% similarity with two serovars, *Canicola* (AGO95576.1) and *Serio hardjo* (AFC76104.1). *Serio hardjo* (AFC76104.1) exhibited 100% similarity with *Serio hardjo* (AGO9557.1) and *Canicola* (AGO95576.1). The lowest level of similarity and divergence, namely 98.7%, was observed between the two serovars *Pamana* (AGO95573.1) and (AGO95574.1) with *Serio hardjo* (AGO9557.1). Furthermore, the *Canicola* serovar (AEU08469.1) exhibited distinct characteristics when compared to all other ten Iranian serovars, including the same serovar *Canicola* (AGO95576.1).

3.2. Transformation, Expression and Purification of rLip132 Protein

In this study, the Lip132 was successfully expressed in pET32a-competent BL21(DE3) *E. coli* cells, and a 38-kDa size TRX-Lip132 fusion protein in the soluble form was produced. The recombinant plasmid was purified from the transformed cells and identified based on its plasmid size (Figure 4). The protein electrophoresis by SDS-PAGE analysis revealed a distinct band that corresponded to successful induction of full-length 38-kDa Lip132 protein. However, the highest expression of Lip132 recombinant protein was observed during the overnight post-induction incubation at a temperature of 22°C in the presence of 0.5 mM IPTG (Figure 5). Subsequent analysis of the cell lysate post-sonication revealed that the recombinant protein was predominantly found in the upper layer, i.e., the culture medium. The cell culture medium containing rLip132 was collected and purified using an affinity purification method. Based on the results of this procedure, one distinct band was identified, with apparent molecular masses of approximately 38 kilodaltons. The demonstration in Figure 6 presents three elution-purified proteins. The confirmation of the purified protein was evaluated by Western blot analysis using an anti-6x His-Tag antibody, as shown in Figure 7. The constructed Lip132 gene was found to produce a high level of expression of the corresponding protein, with a final concentration of 14.844 milligrams per milliliter.

3.3. Humoral Immune Response in Immunized Mice

To assess the humoral immune responses, the total specific IgG in immunized mice was measured by indirect ELISA, with rLip132 serving as the captured antigen. Utilizing checkerboard titration tests, the final concentration of rLip132 for the antigen capture ELISA was established at 0.850 mg/mL, with optimal dilutions for serum and HRP IgG conjugates determined to be 1:50 and 1:5000, respectively. Prior to the first immunization, no antigen-

specific IgG antibodies were detectable in any of the immunized groups. Furthermore, the levels of specific antibodies in mice immunized with rLip132/adjuvant were found to be higher than those in the group immunized with rLip132 alone. At the onset of the study, all animals exhibited no anti-rLip132 specific antibodies, as demonstrated in Figure 8. Subsequent analysis revealed that the antibody titers were significantly higher in both groups that had received rLip132 with or without adjuvant compared to the other groups ($p < 0.05$). Furthermore, the presence of adjuvant resulted in higher antibody production levels compared to its absence. As illustrated in Figure 8, the levels of IgG began to increase two weeks after immunization, reached a maximum on day 30, and then plateaued until the final day. However, a statistically insignificant difference was observed between the animals that received PBS or adjuvant alone during the designated time frame ($p > 0.05$).

3.4. Evaluation of Cytokine Levels in Immunized Mice

To evaluate the cytokine profile, the production of IFN- γ and IL-4 was measured in the culture supernatants of spleen cells stimulated with the recombinant Lip132 protein (Figure 9). This assessment facilitates comprehension of the immune response elicited by rLip132, with a focus on key cytokines implicated in Th1 and Th2 responses.

3.5. Statistical Analysis

The results of the study demonstrated that IFN- γ levels were elevated in mice immunized with rLip132 in the presence of adjuvant compared to those that had received the antigen without adjuvant ($p < 0.05$) (Figure 9A). Furthermore, the levels of IL-4 were found to be higher in mice immunized with rLip132, irrespective of the presence or absence of adjuvant, in comparison to the two other control groups ($p < 0.05$), as illustrated in Figure 9(B).

4. Discussion

Leptospirosis has been recently included in the list of neglected diseases according to a report by the WHO (2,33). This zoonotic infection is prevalent in tropical and subtropical regions (1,34,35), and in Iran, the highest recorded prevalence is observed in the northern region due to the moist climate (36,37). A significant challenge in the management of this condition is the frequent misdiagnosis of leptospirosis due to its similarity of symptoms to other infectious diseases. Furthermore, the use of common bacterin vaccines (inactivated whole bacteria) in both humans and animals is limited due to numerous factors (7,14,38). The development of novel diagnostic methods and vaccination protocols for the prevention of leptospirosis is imperative, and significant advancements have been made in this domain. The advent of genomic technologies and bioinformatics has facilitated the investigation of protective antigens for bacterial pathogens (11,12). Among these, OMPs have emerged as the most promising candidates for use as antigens in these vaccine formulations.







Figure 4. Electrophoresis of purified recombinant plasmid samples. Lane M. 100 bp plus DNA Marker (Bio Fact), Lane 1-3. The first to third elution's of the purified lip132 in order.



A




B




C

Figure 5. (A) SDS-PAGE analysis was performed on the expressed Lip132 protein in *E. coli* following incubation at 22°C. Lane 1 shows the non-induced cell lysate, while lanes 2 to 4 display cells that were induced with 0.5 mM IPTG at 4, 8, and 16 hours post-induction, respectively. (B) The effect of temperature on Lip132 expression was evaluated using SDS-PAGE analysis. Lane 1 corresponds to expression at 30°C, Lane 2 at 37°C, and Lane 3 at 22°C (C) Lanes 1 to 3 show cells that were induced with IPTG at concentrations 0.1, 0.3 and 0.5 mM, respectively. while Lane 4 represents non-induced cells. M. Unstained Protein Molecular Weight Marker (Thermo scientific, Lithuania).



A



B

Figure 6. Characterization of the purified recombinant LipL32 protein on SDS-PAGE. (A). Lane 1 to 3 show First, Second and third elution's of the LipL32 supernatant after five times washing, respectively. (B). The effect of imidazole concentration in the Elution buffer. Lanes 1-3: Elution's were performed with imidazole concentrations of 0.1 mM and 0.3mM, respectively. M. prestained Protein Molecular Weight Marker (Thermo scientific, Lithuania).



Figure 7. Western blotting of recombinant proteins utilizing HRP conjugated anti-6× His-Tag antibodies. Lane M. unstained protein molecular weight marker (kDa), (Thermo, scientific). Lane 1. His-tag purified Lip132 recombinant protein.




Figure 8. An indirect enzyme-linked immunosorbent assay (sandwich ELISA) was used to measure the levels of anti-rLip132 antibody production in BALB/c mice. The mice were immunized subcutaneously with phosphate-buffered saline (as a control), Freund's adjuvant (as another control) and the recombinant Lip132 with and without adjuvant. Blood samples were collected from the retroorbital venous sinus on day 0 (before immunization) and every ten days for two months to assess the antigen-specific total response in the sera. Y-axis OD490 nm and X-axis days ($p < 0.005$)




Figure 9. The evaluation of IFN- γ (A) and IL-4 (B) levels produced by splenocytes from various immunized mice was conducted. Fourteen days after the final immunization, splenocytes were isolated from the mice and cultured either without stimulation (unstimulated) or in the presence of rLip132 for 60 hours in a CO₂ incubator at 37°C. Absorbance was measured using an indirect ELISA at 450 nm. All experiments were performed in triplicate, and the data presented represent the mean values \pm SD. Statistically significant differences are indicated by * (compared to the rLip132 group). The data represents mean SI of two determinations \pm SD. Y-axis shows IFN- γ and IL-4 concentration (pg/ml) and X-axis represents test groups.

The development of recombinant vaccines utilizing OMPs from bacteria has shown great potential, particularly because these proteins are located at the interface between the pathogen and the host. This strategic positioning renders them promising candidates for vaccine development aimed at enhancing protective immunity against bacterial infections (15,16). OMPs and lipoproteins are key constituents of the leptospiral surface. These proteins have garnered significant attention due to their distribution, conservation, functional importance, and critical role in virulence. Furthermore, bacterial OMPs have been observed to elicit a robust antibody response (48). Consequently, ELISA protocols employing single-OMP antigens have been employed for serodiagnosis, encompassing the leptospiral proteins Lip132, Lip121, Lip141, and OmpL1(20,25,39,40,41). A number of proteins have been identified as promising vaccine candidates. The antigens that have undergone the most rigorous evaluation to date include the Lig (Leptospiral immunoglobulin-like) and Lip132 proteins (42- 45). According to the extant literature, Lip132 is regarded as the most abundant component of the outer membrane that functions as a virulence factor in pathogenic *Leptospira*. Lip132 has the potential to elicit a protective immune response across a wide range of serovars due to its conserved nature among pathogenic *Leptospira* serovars. This characteristic renders it a promising candidate for vaccine development aimed at providing broad protection against leptospirosis. Notably, Lip132 is an adhesive molecule that facilitates interaction with host components in pathogenic strains, but not in non-pathogenic ones (25, 44). Luo et al. demonstrated that Lip132 is a predominant antigen in the humoral response during the course of infection (16). Seixas et al. (26) investigated the potential of employing Lip132 in vaccine platforms to elicit immunity in an animal model, encompassing the rBCG vaccine, DNA vaccine, and subunit vaccine. Their findings indicated that anti-Lip132 antibodies exhibited the capacity to impede the proliferation of *Leptospira* in in vitro settings. It has been demonstrated that both humoral and cellular immunity have prominent roles in the response to leptospirosis. Therefore, cytokines and specific antibodies have been proposed as useful biomarkers of disease outcome in various clinical studies (14). In this study, we sought to prepare, express, purify, and evaluate the humoral and cellular immune responses of recombinant Lip132-based ELISA by measuring the antibody titer and the cytokines IL-4 and IFN- γ from pathogenic leptospira among several prevalent local serovars by immunizing mice. Firstly, a sequence analysis of twenty-four Lip132 sequences available in GenBank was performed at the protein level in pathogenic leptospira, including six serovars from Iran and other countries. The results are shown in Table 1. The analysis of Lip132 protein sequences by MegAlign software reveals a high degree of similarity (100%), as illustrated in Figure 2 (C). A comparison of the two protein structures demonstrates a 100% similarity in the lip132 region, indicating that both the

trx and lip132 segments have independently folded without affecting each other. This independence in folding is of critical importance, as it signifies that the structural integrity of the lip132 protein remains intact, a prerequisite for its function as an immunogenic protein. The structural integrity of lip132 is indicative of the preservation of epitope-specific components of the antigen that are recognized by the immune system. Consequently, it is hypothesized that these structural epitopes will maintain their immunogenic properties, thereby enabling effective stimulation of both cellular and humoral immune responses. This finding is significant for vaccine development and diagnostic applications related to leptospirosis, as it underscores the potential of rLip132 to elicit a robust immune response without interference from the fusion partner. A divergence of 0.03% was identified between the entire sequences (Figure 3A). A comparison of the pattern of sequences among Iranian isolates indicated that Lip132 was a conserved antigen, which showed 0.0020% variation in the phylogenetic tree (Figure 3B). Previously, in another study in 2020, Golab et al. reported 0.8% divergence between Iranian and foreign *Leptospira interrogans* serovars based on Lip141 protein sequences and eight amino acid substitutions identified among local serovars (40). Consequently, the Lip132 gene construct (Figure 1) was designed according to the dominant polymorphism pattern of local prevalent pathogenic *Leptospira* isolates in order to have high coverage and less false negative results. The mature form of rLip132 was a lipoprotein in which the first 20 residues were removed, and the construct was synthesized and cloned into the pET32a+ vector. The codon optimization of the rLip132 gene was employed to enhance its expression in *E. coli*, with the rLip132 protein being expressed in *E. coli* BL21(DE3). To achieve high production levels, various concentrations of IPTG, different induction times, and a temperature shift from 37°C to 22°C were considered as alternatives. The results indicated that the maximum expression of Lip132 occurred at 22°C and 0.5 mM IPTG at 16 hours post induction (Figure 5). The results demonstrate that a high level of Lip132 protein expression was achieved in the soluble fraction and that optimal purification was attained by affinity chromatography (Figure 6) with a quantity of 14.844 mg/ml. Western blotting verified the presence of a single distinct band with an approximate molecular weight of 38 kDAs, as illustrated in Figure 7. In addition, several researchers have successfully cloned and expressed rLip132 in various hosts, including *E. coli* and *P. pastoris* (13,46), employing diverse vectors, such as pET-28b+ (39, Feng et al.), pRSET B (47, Meenambigai, 23 Haake/2000), and pET22b (27, Yaakob). Their findings were consistent with our own, indicating that Lip132 was expressed at high levels. The majority of the studies demonstrated that rLip132 had the potential to serve as an antigen for ELISA testing and could be readily implemented in diagnostic laboratories or subunit vaccines. In consideration of the humoral immune response of the

immunized mice, including total antibody levels against Lip132, as illustrated in Figure 8, it is evident that all the antibodies elicited in the rLip132 groups exhibited levels that were significantly higher than those in the groups that had not received rLip132 ($p < 0.05$). Furthermore, no statistically significant differences were observed between the mice receiving a single dose of Lip132 and those receiving both Lip132 and adjuvant. These results indicated that the Lip132-administered groups exhibited superior responses compared to the other groups, which is a crucial point in differentiating cases of natural infection from vaccination. These findings are consistent with those reported by Murray et al. (48) and Seixas et al. (26), who evaluated rLip132 as a vaccine antigen against leptospirosis and observed the strongest humoral immune response in terms of antibody production. In addition, a body of research has demonstrated that Lip132, when used in conjunction with other OMPs, such as Lip121, Lip141, or OmpL1, has exhibited superior immune responses in comparison to single-gene treatments. This phenomenon can be attributed to the synergistic effect resulting from the combination of these OMPs. (Lin et al. 42, Feng et al. 39, Haake 49). In this experiment, the cytokine profile of splenocytes from rLip132-immunized BALB/c mice exhibited a distinctive secretion of IFN- γ associated with adjuvant compared to groups without adjuvant ($p < 0.05$). However, the IL-4 was not only produced in abundance by the mice that had received the antigen alone, but also in those administered the antigen combined with the adjuvant (Figure 9). An investigation by Feng et al. (39) compared immunization in BALB/c mice with recombinant Lip132 apart or together with other OMPs (Lip132-41-OmpL1). Their findings revealed a rise in cell-mediated immunity with greater levels of IL-2 and IFN- γ both in combination or only Lip132. A prior study carried out during a new therapeutic strategy characterized B- and T-cell combined epitopes of the two OMPs Lip132 and LipL21 in BALB/c mice. The results showed that the secretion of IFN- γ was greater than IL-4 (42). A previous study, conducted as part of a novel therapeutic strategy, examined the combined epitopes of the B- and T-cell receptors for the two OMPs Lip132 and LipL21 in BALB/c mice. The results demonstrated that the secretion of IFN- γ was greater than IL-4 (42). As previously mentioned, the subsets of T helper cells can be classified based on the cytokines they produce (32). Th1 cells, for instance, are known to produce IL-2 and IFN- γ , playing a vital role in guiding cell-mediated responses, which are significant in the clearance of intracellular pathogens. In addition, Th2 cells, which are responsible for humoral responses and the production of antibodies, secrete IL-4 and IL-10 (51, 52). A balanced Th1/Th2 response has been shown to elicit a fully protective response, and vaccination has been demonstrated to be effective in inducing both Th1 and Th2 responses (31). In the present study, an immune response profile was revealed that exhibited a tendency towards a Th2 pattern, with abundant antibody production and synthesis of IL-4.

Conversely, a Th1 response pattern was identified, characterized by INF- γ production. In summary, to the best of our knowledge, this study is the first of its kind to demonstrate the analysis of multiple sequence alignments and to design and produce the Lip132 outer membrane sequences of the most prominent serovars of pathogenic *Leptospira* in Iran. The alignment results indicated an observed divergence of 0.03% among the experimental serovars. rLip132 is expressed in the culture medium at a high level, which has the potential to induce significant levels of anti-Lip132 antibodies, as well as robust IFN- γ responses from Th1 cells and IL-4 responses from Th2 cells. Overall, the recombinant protein elicited a predominant Th1 and Th2-type response, resulting in both humoral and cell-mediated immune responses, with cellular immunity being particularly pronounced. It is noteworthy that rLip132 appears to be a promising candidate for use in the development of subunit vaccines or diagnostic kits. These findings could pave the way for further research using rLip132 to validate ELISA or the stability of vaccines against various serovars of *Leptospira* in animals and humans (mammalian hosts).

Acknowledgment

The authors express their profound gratitude to the dedicated staff of the Microbiology department at the Razi Vaccine and Serum Research Institute, and extend their sincere appreciation to Dr. Narges Golab for her invaluable contributions.

Authors' Contribution

Study concept and design: P.K, M.T.

Acquisition of data: N.B, M.E.

Analysis and interpretation of data: S.S.

Drafting of the manuscript: S.S, N.B.

Critical revision of the manuscript for important intellectual content: P.K, M.T.

Statistical analysis: M.E, M.T.

Administrative, technical, and material support: P.K, M.T, M.E.

Ethics

We hereby declare all ethical standards have been respected in preparation of the submitted article.

Conflict of Interest

The authors declare no conflict of interest.

Funding

This project has received financial support from the Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran, as stipulated in the grant agreement No. 12-18-18-106-96045-961023.

Data Availability

The necessary data can be obtained from the corresponding author upon reasonable request.

References

- Langston CE, Heuter KJ. Leptospirosis: A re-emerging zoonotic disease. *Veterinary Clinics: Small Animal Practice*. 2003;33(4):791-807.
- Adler B, de la Peña Moctezuma A. *Leptospira* and leptospirosis. *Veterinary microbiology*. 2010;140(3-4):287-96.
- Haake D, Levett P. Leptospirosis in humans. *Curr To p Microbiol Immunol*. 2015; 387: 65-97. doi: 10.1007. 978-3-662-45059.
- Torres FDA, Borges ALdSB, Kolesnikovas C, Domit C, Barbosa CB, Carvalho-Costa FA, et al. Pinnipeds carriers of pathogenic *Leptospira*: New data based on molecular characterization. *Research in Veterinary Science*. 2023;155:62-8.
- Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, et al. Global morbidity and mortality of leptospirosis: a systematic review. *PLoS neglected tropical diseases*. 2015;9(9):e0003898.
- Bandara M, Ananda M, Wickramage K, Berger E, Agampodi S. Globalization of leptospirosis through travel and migration. *Globalization and health*. 2014;10:1-9.
- Faisal SM, McDonough SP, Chang Y-F. *Leptospira*: Invasion, pathogenesis and persistence. *The pathogenic spirochetes: Strategies for evasion of host immunity and persistence*. 2012:143-72.
- Marotto PC, Nascimento CM, Eluf-Neto J, Marotto MS, Andrade L, Sztajn bok J, et al. Acute lung injury in leptospirosis: clinical and laboratory features, outcome, and factors associated with mortality. *Clinical Infectious Diseases*. 1999;29(6):1561-3.
- Schreier S, Doungchawee G, Chadsuthi S, Triampo D, Triampo W. Leptospirosis: current situation and trends of specific laboratory tests. *Expert review of clinical immunology*. 2013;9(3):263-80.
- Martínez R, Pérez A, Cruz R, Alvarez A, Armesto M, Fernández C, et al. Efficacy and safety of a vaccine against human leptospirosis in Cuba. *Revista panamericana de salud publica= Pan American journal of public health*. 2004;15(4):249-55.
- Fitzgerald J. Availability of leptospirosis vaccine. *The Veterinary Record*. 2009;164(5):157.
- Koizumi N, Watanabe H. Leptospirosis vaccines: past, present, and future. *Journal of postgraduate medicine*. 2005;51(3):210.
- Klaasen H, Molkenboer M, Vrijenhoek M, Kaashoek M. Duration of immunity in dogs vaccinated against leptospirosis with a bivalent inactivated vaccine. *Veterinary microbiology*. 2003;95(1-2):121-32.
- Barazzone GC, Teixeira AF, Azevedo BO, Damiano DK, Oliveira MP, Nascimento AL, et al. Revisiting the development of vaccines against pathogenic *Leptospira*: innovative approaches, present challenges, and future perspectives. *Frontiers in immunology*. 2022;12:760291.
- Haake DA, Zückert WR. The leptospiral outer membrane. *Leptospira and Leptospirosis*. 2014:187-221.
- Luo D, Xue F, Ojcius DM, Zhao J, Mao Y, Li L, et al. Protein typing of major outer membrane lipoproteins from Chinese pathogenic *Leptospira* spp. and characterization of their immunogenicity. *Vaccine*. 2009;28(1):243-55.
- Yan Y, Chen Y, Liou W, Ding J, Chen J, Zhang J, et al. An evaluation of the serological and epidemiological effects of the outer envelope vaccine to leptospira. *Journal of the Chinese Medical Association: JCMA*. 2003;66(4):224-30.
- Grassmann AA, Kremer FS, Dos Santos JC, Souza JD, Pinto LdS, McBride AJA. Discovery of novel leptospirosis vaccine candidates using reverse and structural vaccinology. *Frontiers in immunology*. 2017;8:463.
- Chalayon P, Chanket P, Boonchawalit T, Chattanadee S, Srimanote P, Kalambaheti T. Leptospirosis serodiagnosis by ELISA based on recombinant outer membrane protein. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 2011;105(5):289-97.
- Fernandes LG, Avelar KE, Romero EC, Heinemann MB, Kirchgatter K, Nascimento AL. A new recombinant multiepitope chimeric protein of *Leptospira interrogans* is a promising marker for the serodiagnosis of leptospirosis. *Tropical Medicine and Infectious Disease*. 2022;7(11):362.
- Cullen PA, Haake DA, Adler B. Outer membrane proteins of pathogenic spirochetes. *FEMS microbiology reviews*. 2004;28(3):291-318.
- Aviat F, Rochereau-Roulet S, Branger C, Estavoyer J, Chatrenet B, Orsonneau J, et al. Synthetic peptide issued from Hap1/LipL32 for new early serodiagnosis of human leptospirosis. *Comparative immunology, microbiology and infectious diseases*. 2010;33(5):375-87.
- Haake DA, Chao G, Zuerner RL, Barnett JK, Barnett D, Mazel M, et al. The leptospiral major outer membrane protein LipL32 is a lipoprotein expressed during mammalian infection. *Infection and immunity*. 2000;68(4):2276-85.
- Dey S, Mohan CM, Kumar TS, Ramadass P, Nainar AM, Nachimuthu K. Recombinant LipL32 antigen-based single serum dilution ELISA for detection of canine leptospirosis. *Veterinary microbiology*. 2004;103(1-2):99-106.
- Boonyod D, Poovorawan Y, Bhattarakosol P, Chirathaworn C. LipL32, an outer membrane protein of *Leptospira*, as an antigen in a dipstick assay for diagnosis of leptospirosis. *Asian Pacific Journal of Allergy and Immunology*. 2005;23(2-3):133.
- Seixas FK, Fernandes CH, Hartwig DD, Conceicao FR, Aleixo JAG, Dellagostin OA. Evaluation of different ways of presenting LipL32 to the immune system with the aim of developing a recombinant vaccine against leptospirosis. *Canadian Journal of Microbiology*. 2007;53(4):472-9.
- Yaakob Y, Rodrigues KF, Opook F, William T, John DV. Recombinant LipL32 protein developed using a synthetic gene detects *Leptospira*-specific antibodies in human serum samples. *The Malaysian journal of medical sciences: MJMS*. 2017;24(5):44.
- Yeoh TS, Tang TH, Citartan M. Isolation of a novel DNA aptamer against LipL32 as a potential diagnostic agent

- for the detection of pathogenic *Leptospira*. *Biotechnology Journal*. 2023;18(3):2200418.
29. Govindan P, Manjusha P, Saravanan KM, Natesan V, Salmen SH, Alfarraj S, et al. Expression and preliminary characterization of the potential vaccine candidate LipL32 of leptospirosis. *Applied Nanoscience*. 2021:1-15.
 30. Fraga TR, Barbosa AS, Isaac L. Leptospirosis: aspects of innate immunity, immunopathogenesis and immune evasion from the complement system. *Scandinavian journal of immunology*. 2011;73(5):408-19.
 31. Dellagostin OA, Grassmann AA, Hartwig DD, Félix SR, da Silva EF, McBride AJ. Recombinant vaccines against leptospirosis. *Human vaccines*. 2011;7(11):1215-24.
 32. Reis EA, Hagan JE, Ribeiro GS, Teixeira-Carvalho A, Martins-Filho OA, Montgomery RR, et al. Cytokine response signatures in disease progression and development of severe clinical outcomes for leptospirosis. *PLoS neglected tropical diseases*. 2013;7(9):e2457.
 33. Qiagen A. handbook for high-level expression and purification of 6xHis-tagged proteins. Qiagen, Chatsworth, Calif, USA. 2003.
 34. Torgerson PR, Hagan JE, Costa F, Calcagno J, Kane M, Martinez-Silveira MS, et al. Global burden of leptospirosis: estimated in terms of disability adjusted life years. *PLoS neglected tropical diseases*. 2015;9(10):e0004122.
 35. Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, et al. Leptospirosis: a zoonotic disease of global importance. *The Lancet infectious diseases*. 2003;3(12):757-71.
 36. Putz EJ, Nally JE. Investigating the immunological and biological equilibrium of reservoir hosts and pathogenic leptospira: balancing the solution to an acute problem? *Frontiers in microbiology*. 2020;11:2005.
 37. Khaki P. Clinical laboratory diagnosis of human leptospirosis. *Int J Enteric Pathog*. 2016;4(1):1-7.
 38. Bakhshandeh N, Tebianian M, Khaki P, Esmaelizad M, Saadatmand S. Development of an In-house Indirect ELISA Test as a Diagnostic Tool for Bovine Leptospirosis. *International Journal of Enteric Pathogens*. 2021;9(2):47-51.
 39. Maia MA, Bettin EB, Barbosa LN, de Oliveira NR, Bunde TT, Pedra ACK, et al. Challenges for the development of a universal vaccine against leptospirosis revealed by the evaluation of 22 vaccine candidates. *Frontiers in cellular and infection microbiology*. 2022:1503.
 40. Feng C, Li Q, Zhang X, Dong K, Hu B, Guo X. Immune strategies using single-component LipL32 and multi-component recombinant LipL32-41-OmpL1 vaccines against leptospira. *Brazilian Journal of Medical and Biological Research*. 2009;42:796-803.
 41. Golab N, Khaki P, Harzandi N, Esmaelizad M, Tebianian M. Expression and purification of the LipL41, a surface-exposed lipoprotein antigen of pathogenic *Leptospira* spp. *Veterinarski arhiv*. 2020;90(3):297-305.
 42. Teixeira AF, Cavenague MF, Kochi LT, Fernandes LG, Souza GO, de Souza Filho AF, et al. Immunoprotective activity induced by leptospiral outer membrane proteins in hamster model of acute leptospirosis. *Frontiers in Immunology*. 2020;11:568694.
 43. Lin Xa, Zhao J, Qian J, Mao Y, Pan J, Li L, et al. Identification of immunodominant B-and T-cell combined epitopes in outer membrane lipoproteins LipL32 and LipL21 of *Leptospira interrogans*. *Clinical and Vaccine Immunology*. 2010;17(5):778-83.
 44. Haake DA, Matsunaga J. Leptospiral immunoglobulin-like domain proteins: Roles in virulence and immunity. *Frontiers in Immunology*. 2021;11:579907.
 45. Hauk P, Macedo F, Romero EC, Vasconcelos SIA, de Moraes ZM, Barbosa AS, et al. In LipL32, the major leptospiral lipoprotein, the C terminus is the primary immunogenic domain and mediates interaction with collagen IV and plasma fibronectin. *Infection and immunity*. 2008;76(6):2642-50.
 46. Vieira ML, Atzingen MV, Oliveira TR, Oliveira R, Andrade DM, Vasconcelos SA, et al. In vitro identification of novel plasminogen-binding receptors of the pathogen *Leptospira interrogans*. *PloS one*. 2010;5(6):e11259.
 47. Golab N, Khaki P, Tebianian M, Esmaelizad M, Harzandi N. Recombinant outer membrane protein LipL41 from *Leptospira interrogans* robust immune responses in mice model. *Iranian Journal of Microbiology*. 2024;16(4):545.
 48. Hartwig DD, Baceo KL, de Oliveira PD, Oliveira TL, Seixas FK, Amaral MG, et al. Mannosylated LigANI produced in *Pichia pastoris* protects hamsters against leptospirosis. *Current microbiology*. 2014;68:524-30.
 49. Gharakhani M, Ghasemi MF, Khaki P, Esmaelizad M, Tebianian M. Improvement the Expression and Purification of Loa22: A Lipoprotein with OmpA domain from Pathogenic *Leptospira* Serovars. 2022.
 50. Plotkin SA. Updates on immunologic correlates of vaccine-induced protection. *Vaccine*. 2020;38(9):2250-7.
 51. Senavirathna I, Rathish D, Agampodi S. Cytokine response in human leptospirosis with different clinical outcomes: a systematic review. *BMC Infectious Diseases*. 2020;20(1):1-8.